Opening “Huntington Disease: 2025 Update
“Huntington Disease: 2025 Update
- Length
- 1 h 2 min
- Level
- Undergraduate
- Recorded
- University of Louisville2025
Chapter 1 of 10: Before the lecture
Traces Huntington disease genetics, symptom triads, and emerging oral splice-modifying therapies.
Huntington disease is a monogenic neurodegenerative disorder caused by CAG repeat expansions on chromosome four. The clinical presentation features a triad of motor, behavioral, and cognitive symptoms, with chorea serving as a prominent early motor sign. Treatment focuses on symptom management using VMAT2 inhibitors like tetrabenazine and deutetrabenazine to deplete presynaptic dopamine and control chorea. The lecture details the Huntington's Disease Integrated Staging System to track progression from pre-symptomatic stages to severe functional decline. Ongoing therapeutic trials explore novel disease-modifying agents such as splice modifiers and viral vector therapies.
Huntington disease is a monogenic neurodegenerative disorder caused by CAG repeat expansions on chromosome four. The clinical presentation features a triad of motor, behavioral, and cognitive symptoms, with chorea serving as a prominent early motor sign. Treatment focuses on symptom management using VMAT2 inhibitors like tetrabenazine and deutetrabenazine to deplete presynaptic dopamine and control chorea. The lecture details the Huntington's Disease Integrated Staging System to track progression from pre-symptomatic stages to severe functional decline. Ongoing therapeutic trials explore novel disease-modifying agents such as splice modifiers and viral vector therapies.
Cell 1993;73:971-983
Nature Genetics, 1993; 4:387-92
A Physician's Guide to the Management of HD, 2nd Ed.1999
Movement Disorders: Neurologic Principles and Practice 2004;589-96
Movement Disorders: Neurologic Principles and Practice 2004;571-88
Movement Disorders: Neurologic Principles and Practice

This lecture
Talk 16 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Psychiatr Clin North Am. 1997;20:791–807
Arch Neurol. 2001;58:273–8
J Neurol. 2003;250:545–41
Mov Disord. 2008;23:970–6
Kirkwood, et al, 2001
Klawans and Kramer, 1980
Cudkowicz, et al, 1999
Frank, et al, 2004
Huntington Study Group, Mov Disord. 1996;11:135–42
Grimbergen YA, et al. Mov Disord. 2008;23:970–6
Xenazine Full Prescribing Information
Pettibone DJ, Totaro JA, Pflueger AB. Eur J Pharmacol. 1984;102(3):425–430
Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants
Beglinger et al., Psychiatry Res. 2010;178(4):416-423